The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range
Open accessAbstract
PURPOSE: Prostate specific antigen and free prostate specific antigen have limited specificity to detect clinically significant, curable prostate cancer, leading to unnecessary biopsy, and detection and treatment of some indolent tumors. Specificity to detect clinically significant prostate cancer may be improved by [-2]pro-prostate specific antigen. We evaluated [-2]pro-prostate specific antigen, free prostate specific antigen and prostate specific antigen using the formula, ([-2]pro-prostate specific antigen/free prostate specific antigen × prostate specific antigen(1/2)) to enhance specificity to detect overall and high grade prostate cancer. MATERIALS AND METHODS: We enrolled 892 men with no history of prostate cancer, normal rectal examination, prostate specific antigen 2 to 10 ng/ml and 6-core or greater prostate biopsy in a prospective multi-institutional trial. We examined the relationship of serum prostate specific antigen, free-to-total prostate specific antigen and the prostate health index with biopsy results. Primary end points were specificity and AUC using the prostate health index to detect overall and Gleason 7 or greater prostate cancer on biopsy compared with those of free-to-total prostate specific antigen. RESULTS: In the 2 to 10 ng/ml prostate specific antigen range at 80% to 95% sensitivity the specificity and AUC (0.703) of the prostate health index exceeded those of prostate specific antigen and free-to-total prostate specific antigen. An increasing prostate health index was associated with a 4.7-fold increased risk of prostate cancer and a 1.61-fold increased risk of Gleason score greater than or equal to 4 + 3 = 7 disease on biopsy. The AUC of the index exceeded that of free-to-total prostate specific antigen (0.724 vs 0.670) to discriminate prostate cancer with Gleason 4 or greater + 3 from lower grade disease or negative biopsy. Prostate health index results were not associated with age and prostate volume. CONCLUSIONS: The prostate health index may be useful in prostate cancer screening to decrease unnecessary biopsy in men 50 years old or older with prostate specific antigen 2 to 10 ng/ml and negative digital rectal examination with minimal loss in sensitivity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1990) · Choice Reviews Online · doi:10.5860/choice.27-3338 · Cited by 35,305
DeLong, E. R., DeLong, D. M., & Clarke-Pearson, D. L. (1988) · Biometrics · doi:10.2307/2531595 · Cited by 22,649
The Jackknife, the Bootstrap and Other Resampling Plans
Efron, B. (1982) · Society for Industrial and Applied Mathematics eBooks · doi:10.1137/1.9781611970319 · Cited by 8,120
Kupper, L. L., Hosmer, D. W., & Lemeshow, S. (1990) · Journal of the American Statistical Association · doi:10.2307/2290035 · Cited by 7,599
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Self-citationBetter Bootstrap Confidence Intervals
Efron, B. (1987) · Journal of the American Statistical Association · doi:10.1080/01621459.1987.10478410 · Cited by 3,364
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
The Jackknife: The Bootstrap and Other Resampling Plans.
Low, L. Y., & Efron, B. (1983) · Journal of the American Statistical Association · doi:10.2307/2288218 · Cited by 2,702
Thompson, I. M., Pauler, D. K., Goodman, P. J., Tangen, C. M., Lucia, M. S., Parnes, H. L., Minasian, L. M., Ford, L. G., Lippman, S. M., Crawford, E. D., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031918 · Cited by 2,446
The Statistical Evaluation of Medical Tests for Classification and Prediction
Pepe, M. S. (2003) · doi:10.1093/oso/9780198509844.001.0001 · Cited by 2,198
The Statistical Evaluation of Medical Tests for Classification and Prediction
(2005) · Technometrics · doi:10.1198/tech.2005.s278 · Cited by 1,899
Catalona, W. J., Richie, J. P., Ahmann, F. R., Hudson, M. A., Scardino, P. T., Flanigan, R. C., Dekernion, J. B., Ratliff, T. L., Kavoussi, L. R., Dalkin, B. L., et al. (1994) · Journal of Urology · doi:10.1016/s0022-5347(17)35233-3 · Cited by 1,592
Self-citationCatalona, W. J., Partin, A. W., Slawin, K. M., Brawer, M. K., Flanigan, R. C., Patel, A., Richie, J. P., deKernion, J. B., Walsh, P. C., Scardino, P. T., et al. (1998) · JAMA · doi:10.1001/jama.279.19.1542 · Cited by 1,162
Self-citationJemal, A., Thun, M. J., Ries, L. A. G., Howe, H. L., Weir, H. K., Center, M. M., Ward, E., Wu, X.-C., Eheman, C., Anderson, R., et al. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn389 · Cited by 957
Mortality results from the Göteborg randomised population-based prostate-cancer screening trial
Hugosson, J., Carlsson, S., Aus, G., Bergdahl, S., Khatami, A., Lodding, P., Pihl, C.-G., Stranne, J., Holmberg, E., & Lilja, H. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70146-7 · Cited by 936
Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin
Lilja, H., Christensson, A., Dahlén, U., Matikainen, M. T., Nilsson, O., Pettersson, K., & Lövgren, T. (1991) · Clinical Chemistry · doi:10.1093/clinchem/37.9.1618 · Cited by 910
Welch, H. G., & Albertsen, P. C. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp278 · Cited by 575
Jansen, F. H., van Schaik, R. H. N., Kurstjens, J., Horninger, W., Klocker, H., Bektic, J., Wildhagen, M. F., Roobol, M. J., Bangma, C. H., & Bartsch, G. (2010) · European Urology · doi:10.1016/j.eururo.2010.02.003 · Cited by 259
Self-citationSokoll, L. J., Sanda, M. G., Feng, Z., Kagan, J., Mizrahi, I. A., Broyles, D. L., Partin, A. W., Srivastava, S., Thompson, I. M., Wei, J. T., et al. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0007 · Cited by 202
Self-citationKrumholtz, J. S., Carvalhal, G. F., Ramos, C. G., Smith, D. S., Thorson, P., Yan, Y., Humphrey, P. A., Roehl, K. A., & Catalona, W. J. (2002) · Urology · doi:10.1016/s0090-4295(02)01875-7 · Cited by 170
Self-citationA precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum
Mikolajczyk, S. D., Grauer, L. S., Millar, L. S., et al. (1997) · Urology · doi:10.1016/s0090-4295(97)00449-4 · Cited by 167
Proenzyme Forms of Prostate-Specific Antigen in Serum Improve the Detection of Prostate Cancer
Mikolajczyk, S. D., Catàlona, W. J., Evans, C. L., et al. (2004) · Clinical Chemistry · doi:10.1373/clinchem.2003.026823 · Cited by 156
Sokoll, L. J., Wang, Y., Feng, Z., Kagan, J., Partin, A. W., Sanda, M. G., Thompson, I. M., & Chan, D. W. (2008) · The Journal of Urology · doi:10.1016/j.juro.2008.04.015 · Cited by 110
Self-citation
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Prevention and early detection of prostate cancer
Cuzick, J., Thorat, M. A., Andriole, G., Brawley, O. W., Brown, P. H., Culig, Z., Eeles, R. A., Ford, L. G., Hamdy, F. C., Holmberg, L., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70211-6 · Cited by 495
Multiparametric MRI for prostate cancer diagnosis: current status and future directions
Stabile, A., Giganti, F., Rosenkrantz, A. B., Taneja, S. S., Villeirs, G., Gill, I. S., Allen, C., Emberton, M., Moore, C. M., & Kasivisvanathan, V. (2020) · Nature Reviews Urology · doi:10.1038/s41585-019-0212-4 · Cited by 398
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment
Tomlins, S. A., Day, J. R., Lonigro, R. J., Hovelson, D. H., Siddiqui, J., Kunju, L. P., Dunn, R. L., Meyer, S., Hodge, P., Groskopf, J., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.04.039 · Cited by 393
Self-citationNCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016
Carroll, P. R., Parsons, J. K., Andriole, G., Bahnson, R. R., Castle, E. P., Catalona, W. J., Dahl, D. M., Davis, J. W., Epstein, J. I., Etzioni, R. B., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0060 · Cited by 342
Self-citation
Metadata
- Authors
- Catalona, W. J., Partin, A. W., Sanda, M. G., Wei, J. T., Klee, G. G., Bangma, C. H., Slawin, K. M., Marks, L. S., Loeb, S., Broyles, D. L., Shin, S. S., Cruz, A. B., Chan, D. W., Sokoll, L. J., Roberts, W. L., van Schaik, R. H. N., & Mizrahi, I. A.
- Venue
- Journal of Urology
- Published
- 2011-05
- Volume
- 185
- Issue
- 5
- Pages
- 1650-1655
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W2148934838
- Cited by
- 502
- References
- 23
- FWCI
- 23.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.